Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2019. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3761802013 | Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3761803015 | Product containing precisely metformin hydrochloride 1 gram and saxagliptin (as saxagliptin hydrochloride) 5 milligram/1 each prolonged-release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Is a | Metformin hydrochloride + saxagliptin | false | Inferred relationship | Some | ||
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Is a | Combination oral hypoglycemic | false | Inferred relationship | Some | ||
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Is a | Product manufactured as oral dose form (product) | false | Inferred relationship | Some | ||
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Has active ingredient | Metformin hydrochloride | false | Inferred relationship | Some | ||
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Has active ingredient | Saxagliptin (substance) | false | Inferred relationship | Some | ||
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Has manufactured dose form | Extended-release tablet | false | Inferred relationship | Some | ||
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Is a | Metformin-containing product in oral dose form | false | Inferred relationship | Some | ||
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Has manufactured dose form | Prolonged-release oral tablet | true | Inferred relationship | Some | ||
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Is a | TEMPORARY parent for CDs that are not updated | false | Inferred relationship | Some | ||
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 2 | |
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 1 | |
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 2 | |
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Count of base of active ingredient | 2 | false | Inferred relationship | Some | ||
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Is a | Metformin and saxagliptin only product in oral dose form | true | Inferred relationship | Some | ||
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Has presentation strength numerator value | 1 | false | Inferred relationship | Some | 1 | |
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Has precise active ingredient | Saxagliptin hydrochloride (substance) | true | Inferred relationship | Some | 2 | |
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Has presentation strength numerator unit | g | true | Inferred relationship | Some | 1 | |
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Has precise active ingredient | Metformin hydrochloride | true | Inferred relationship | Some | 1 | |
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Has basis of strength substance (attribute) | Metformin hydrochloride | true | Inferred relationship | Some | 1 | |
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Has presentation strength numerator value | 5 | false | Inferred relationship | Some | 2 | |
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
| Metformin hydrochloride 1 g and saxagliptin (as saxagliptin hydrochloride) 5 mg prolonged-release oral tablet | Has basis of strength substance (attribute) | Saxagliptin (substance) | true | Inferred relationship | Some | 2 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR